

NEP(1-40)

Cat. No.:	HY-P1242
CAS No.:	475221-20-6
Molecular Formula:	C ₂₀₆ H ₃₂₄ N ₅₆ O ₆₅
Molecular Weight:	4625.11
Sequence:	Arg-Ile-Tyr-Lys-Gly-Val-Ile-Gln-Ala-Ile-Gln-Lys-Ser-Asp-Glu-Gly-His-Pro-Phe-Arg-Ala-Tyr-Leu-Glu-Ser-Glu-Val-Ala-Ile-Ser-Glu-Glu-Leu-Val-Gln-Lys-Tyr-Ser-Asn-Ser-NH ₂
Sequence Shortening:	RIYKGVIAIQKSDEGHPFRAYLESEVAISEELVQKYSNS-NH ₂
Target:	Others
Pathway:	Others
Storage:	Sealed storage, away from moisture Powder -80°C 2 years -20°C 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

BIOLOGICAL ACTIVITY

Description	NEP(1-40) is a Nogo-66 receptor (NgR) antagonist peptide, reversing the injury-induced shift in distribution of microglia morphologies by limiting myelin-based inhibition ^[1] .								
In Vivo	<p>NEP(1-40) (89 µg/kg, ip, 15 min and 19 h post-injury) administration further shifts distributions of microglia away from an injury-induced activated morphology towards greater proportions of rod and macrophage-like morphologies^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table> <tr> <td>Animal Model:</td> <td>74 male Sprague-Dawley rats (328-377 g)^[1].</td> </tr> <tr> <td>Dosage:</td> <td>89 µg/kg (97.5% PBS and 2.5% DMSO).</td> </tr> <tr> <td>Administration:</td> <td>IP, 15 min and 19 h post-injury.</td> </tr> <tr> <td>Result:</td> <td>Reduced NgR function immediately post-injury. Increased number of amoeboid microglia/macrophages at 2 days post-injury</td> </tr> </table>	Animal Model:	74 male Sprague-Dawley rats (328-377 g) ^[1] .	Dosage:	89 µg/kg (97.5% PBS and 2.5% DMSO).	Administration:	IP, 15 min and 19 h post-injury.	Result:	Reduced NgR function immediately post-injury. Increased number of amoeboid microglia/macrophages at 2 days post-injury
Animal Model:	74 male Sprague-Dawley rats (328-377 g) ^[1] .								
Dosage:	89 µg/kg (97.5% PBS and 2.5% DMSO).								
Administration:	IP, 15 min and 19 h post-injury.								
Result:	Reduced NgR function immediately post-injury. Increased number of amoeboid microglia/macrophages at 2 days post-injury								

CUSTOMER VALIDATION

- Oncol Lett. May 27, 2022.

See more customer validations on www.MedChemExpress.com

REFERENCES

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA